drugset
drugset / Trial / NCT00830869

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

NCT00830869 ↗

Phase 1 Completed 116 enrolled Millennium Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase 1, dose escalation study of IXAZOMIB. The primary purpose of this study is to determine the safety profile, establish the maximum tolerated dose, and inform the phase 2 dose of IXAZOMIB administered intravenously in participants with nonhematologic malignancies.

Timeline

Start
2009-03-02
Primary completion
2012-04-20
Completion
2012-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown 0.125 mg/m2 Intravenous
Subject Ixazomib Unknown 0.25 mg/m2 Intravenous
Subject Ixazomib Unknown 0.5 mg/m2 Intravenous
Subject Ixazomib Unknown 1 mg/m2 Intravenous
Subject Ixazomib Unknown 1.33 mg/m2 Intravenous
Subject Ixazomib Unknown 1.76 mg/m2 Intravenous
Subject Ixazomib Unknown 2.34 mg/m2 Intravenous

Indications

No indication recorded.